Traynor Capital Management Inc. increased its stake in Galectin Therapeutics Inc. (NASDAQ:GALT – Free Report) by 29.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 55,670 shares of the company’s stock after purchasing an additional 12,799 shares during the quarter. Traynor Capital Management Inc.’s holdings in Galectin Therapeutics were worth $72,000 at the end of the most recent quarter.
Other large investors have also added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC lifted its holdings in Galectin Therapeutics by 46.4% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 51,369 shares of the company’s stock valued at $66,000 after acquiring an additional 16,271 shares during the period. Marshall Wace LLP bought a new position in shares of Galectin Therapeutics in the 2nd quarter worth approximately $43,000. JPMorgan Chase & Co. lifted its stake in shares of Galectin Therapeutics by 161.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 30,628 shares of the company’s stock worth $84,000 after purchasing an additional 18,907 shares during the period. Rhumbline Advisers purchased a new position in shares of Galectin Therapeutics in the second quarter worth approximately $44,000. Finally, Geode Capital Management LLC grew its position in Galectin Therapeutics by 2.5% during the third quarter. Geode Capital Management LLC now owns 862,542 shares of the company’s stock valued at $2,372,000 after buying an additional 20,817 shares during the period. Institutional investors own 11.68% of the company’s stock.
Galectin Therapeutics Trading Up 1.7 %
Galectin Therapeutics stock opened at $1.23 on Friday. Galectin Therapeutics Inc. has a 12-month low of $0.73 and a 12-month high of $4.27. The firm has a market capitalization of $77.19 million, a price-to-earnings ratio of -1.68 and a beta of 0.83. The firm has a 50 day moving average of $1.78 and a 200 day moving average of $2.28.
Insider Transactions at Galectin Therapeutics
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on GALT shares. StockNews.com cut shares of Galectin Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, December 30th. HC Wainwright reiterated a “neutral” rating on shares of Galectin Therapeutics in a research report on Friday, December 27th.
View Our Latest Research Report on Galectin Therapeutics
About Galectin Therapeutics
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
Read More
- Five stocks we like better than Galectin Therapeutics
- Manufacturing Stocks Investing
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- ETF Screener: Uses and Step-by-Step Guide
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- What Are Dividends? Buy the Best Dividend Stocks
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Want to see what other hedge funds are holding GALT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Galectin Therapeutics Inc. (NASDAQ:GALT – Free Report).
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.